ANVS · Annovis Bio, Inc.
$1.64
-0.06 (-3.53%)
At close · Sep 3
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has concluded that substantial doubt exists about the Company's ability to continue as a going concern. Management's plans to mitigate this risk include raising additional capital through equity financings, debt, or other potential alternatives. Management's plans may also include the deferral of certain operating expenses unless and until additional capital is received. However, there can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company, or that the Company will be successful in deferring certain operating expenses. As such, Management has concluded that such plans do not alleviate the aforementioned substantial doubt.”View the 10-Q filed Aug 14, 2026
Market Cap
$72.43M
Shares
42.61M
ANVS metrics
47 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$1.70
Market cap
$72.43M
Price action
19 metricsPrice change (1W)
-7.1%
Price change (30D)
-1.7%
Price change (3M)
-9.1%
Price change (6M)
-34.5%
Price change (YTD)
-51.2%
Price change (1Y)
-26.8%
Trailing year
Price change (5Y)
-95.4%
52-week high
$5.10
52-week low
$1.59
Change from 52-week high
-66.9%
Change from 52-week low
+6.3%
Annualized volatility
89.6%
Beta
1.9
RSI (14D)
42.1
Price vs SMA 50
-5.8%
Price vs SMA 200
-31.8%
Avg volume (3M)
782,788
Relative volume
0.6
Average dollar volume
$1.42M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
42.61M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-67.6%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2025-08-12
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$49.53M
Net income (TTM)
−$49.52M
Trailing 12 months
Diluted EPS (TTM)
$-1.79
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+92.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-224.7%
Debt / equity
—
Current ratio
—
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$18.73M
Latest balance sheet
Cash & equivalents
$18.73M
Total assets
$22.04M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$43.34M
Capital expenditures (TTM)
—
R&D (TTM)
$43.77M
SG&A (TTM)
—
Stock compensation (TTM)
$2.59M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
63
13F filer change QoQ
+5
Institutional ownership
28.3%
Short interest
3 metricsShort interest
11.7%
Latest settlement · 8.2 days to cover
Days to cover
8.2d
Short-squeeze score
63 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged
Key facts
CIK
1477845
CUSIP
03615A108
13F (30d)
52 filings
50 filers
Visit website
Investor relations